[Clinical study of irinotecan plus infusional fluorouracil/l-leucovorin (FOLFIRI) in patients with fluoropyrimidine-resistant metastatic colorectal cancer].
The clinical efficacy and safety of irinotecan plus infusional fluorouracil/l-leucovorin (FOLFIRI) in patients with fluoropyrimidine-resistant metastatic colorectal cancer were studied retrospectively. 20 patients were treated with FOLFIRI at our hospital between October 2003 and November 2005. The objective overall response rate was 28% (5/18; 95% confidence interval, 9.7-54%). The disease control rate (CR+PR+SD) was 61%. The most frequent grade 3 to 4 adverse event was neutropenia, and it was seen in 50%. Non-hematological toxicities were mild. The median survival time was 11 months. The 1-year survival rate was 34%. This study showed the activity and safety of FOLFIRI in practice.
Moriwaki
Toshikazu
T
Dept. of Internal Medicine, National Hospital Organization Shikoku Cancer Center.
Hyodo
Ichinosuke
I
Nishina
Tomohiro
T
Kajiwara
Takeshi
T
Kataoka
Junro
J
Hori
Shinichiro
S
Nasu
Junichirou
J
Imamine
Satoshi
S
Iguchi
Haruo
H
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002166:Camptothecin / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000401:mortality; D019008:Drug Resistance, Neoplasm; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D002955:Leucovorin / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011743:Pyrimidines / Q000494:pharmacology; D012189:Retrospective Studies; D015996:Survival Rate; D016896:Treatment Outcome
D011743:Pyrimidines; D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin